Mepsevii (vestronidase alfa)
Effective 09/18/2019

<table>
<thead>
<tr>
<th>Plan</th>
<th>☒ MassHealth</th>
<th>☒ Commercial/Exchange</th>
<th>Program Type</th>
<th>☒ Prior Authorization</th>
<th>☒ Quantity Limit</th>
<th>☒ Step Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benefit</td>
<td>☐ Pharmacy Benefit</td>
<td>☒ Medical Benefit (NLX)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specialty Limitations</td>
<td>N/A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Specialty Medications**

All Plans

Phone: 866-814-5506
Fax: 866-249-6155

**Non-Specialty Medications**

MassHealth

Phone: 877-433-7643
Fax: 866-255-7569

Commercial

Phone: 800-294-5979
Fax: 888-836-0730

Exchange

Phone: 855-582-2022
Fax: 855-245-2134

**Medical Specialty Medications (NLX)**

All Plans

Phone: 844-345-2803
Fax: 844-851-0882

**Contact Information**

**Exceptions**

N/A

**Overview**

Vestronidase alfa is a recombinant human beta-glucuronidase (GUS), which provides exogenous GUS enzyme for uptake into cellular lysosomes. Mannose-6-phosphate (M6P) residues on the oligosaccharide chains allow binding of the enzyme to cell surface receptors, leading to cellular uptake of the enzyme, targeting to lysosomes and subsequent catabolism of accumulated glycosaminoglycans (GAGs) in affected tissues.

**Coverage Guidelines**

Authorization may be granted for members who are currently receiving treatment with Mepsevii, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs. **OR**

Authorization may be granted if the member meets all following criteria and documentation has been submitted:

1. The member is diagnosed with mucopolysaccharidosis VII (MPS VII, Sly syndrome)
2. An assay of enzyme activity results from genetic testing showing mutation in the beta glucuronidase gene is submitted
3. The member’s current weight is provided.

**Limitations**

1. Authorization will be granted for 6 months

**References**

1. Mepsevii (vestronidase Alfa-vjbk) [prescribing information]. Novato, CA: Ultragenyx Pharmaceutical Inc; November 2017
2. Deletion mapping of plasminogen activator inhibitor, type I (PLANH1) and beta-glucuronidase (GUSB) in 7q21----q22. Cytogenet Cell Genet 1991; 56:152.

Review History
09/18/2019 – Reviewed
07/22/2020 – Reviewed July P&T Mtg; no clinical updates

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.